New bone cement that delivers antibiotics to treat infections
Official title: Nanostructured degradable bone cement for delivering novel antibiotics
Funded at Brigham and Women's Hospital · NIH-10917431 · Data updated 2026-11-12
This study is testing a new kind of bone cement that can release antibiotics directly to infected bones, especially for people with diabetes, to help them heal better and lower the chances of serious complications like amputation.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $683,565 |
| NIH project number | 5R01EB035485-02 |
| Project ID | NIH-10917431 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are diabetic patients who are at risk of developing bone infections or have existing osteomyelitis.
✕Less likely to help
Patients without diabetes or those who do not have bone infections may not benefit from this research.
What this research studies
This research focuses on developing a novel type of bone cement that can deliver antibiotics directly to infected bone tissue, particularly for patients with diabetes who are at high risk for bone infections. The approach aims to overcome current treatment limitations, such as the formation of biofilms and antibiotic resistance, by creating a degradable cement that releases antibiotics effectively and promotes bone regeneration. Patients may benefit from improved healing and reduced risk of amputation through this innovative treatment method.
Why it matters
Potential benefit: If successful, this research could significantly enhance the treatment of bone infections and improve recovery outcomes for patients with diabetes.
How similar studies have gone: Previous research has shown promise in using drug-device combinations for treating infections, indicating potential success for this novel approach.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Sengupta, Shiladitya — Brigham and Women's Hospital
- Study coordinator: Sengupta, Shiladitya
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.